Omalizumab use during pregnancy for CIU: a tertiary care experience.

Journal Article

The treatment of antihistamine and steroid resistant Chronic Idiopathic Urticaria (CIU) during pregnancy poses a challenge due to teratogenicity of immunosuppressants. Omalizumab is a recently FDA approved therapy for CIU and is classified as pregnancy category B. We present an initial series of subjects treated at a tertiary care center for antihistamine and steroid resistant CIU with omalizumab who became pregnant during therapy.

Full Text

Pubmed Central version
Link to Item

Duke Authors

Radojicic, Cristine

Cited Authors

Cuervo-Pardo, L; Barcena-Blanch, M; Radojicic, C

Published Date

July 2016

Published In

European Annals of Allergy and Clinical Immunology

Volume / Issue

48 / 4

Start / End Page

145 - 146

PubMed ID

27425170

Pubmed Central ID

27425170

International Standard Serial Number (ISSN)

1764-1489

Language

Conference Location

Italy